Roivant Sciences Ltd. Overview
ROIV market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ROIV price chart · 1M
- O
- 36.79
- H
- 38.74
- L
- 36.66
- C
- 38.73
- Vol
- 297,240.00
Daily history from Dec 9, 2020
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $36.79
- Previous Close
- $36.63
- Day High
- $38.74
- Day Low
- $36.66
- 52 Week High
- $42.49
- 52 Week Low
- $19.88
- 7 Day Return
- +4.93%
- 30 Day Return
- +11.42%
- 90 Day Return
- +8.21%
- 1 Year Return
- +88.47%
- Daily Notional Volume
- $11.5M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.43 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.07 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,535.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $19.32 – $42.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $26.5B · P/B 4.38 · P/S 3,511.88.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Roivant and Priovant Announce Positive Phase 3 Results for Brepocitinib in Non-Infectious UveitisFiscal.ai ·
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Globenewswire Inc ·
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Globenewswire Inc ·
8-K filing — Roivant Sciences Ltd. (ROIV)SEC EDGAR ·